As of Friday, January 23, Nektar Therapeutics’s NKTR share price has surged by 7.36%, which has investors questioning if this ...
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...
A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...
As of Friday, January 23, Coherus Oncology, Inc.’s CHRS share price has surged by 21.70%, which has investors questioning if ...
Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...
Therapies market, valued at USD 16.7 million in 2024, is expected to register robust revenue CAGR of 44.6%.Request free copy of this report: 13, 2026- The growing incidence of autoimmune disorders ...
Gubernatorial candidate Dave Bronson, a Republican former mayor of Anchorage, said Wednesday that he has selected Fairbanks ...
10d
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...
A researcher is planning on investigating potential treatments aimed at the root causes of type 1 diabetes. At the (MUSC), ...
TangGene names former GSK SVP Catherine Sohn as Senior Strategic Advisor, strengthening leadership as it advances a first-in-class in-vivo CD8⁺ Treg therapy. TangGene’s in-vivo CD8⁺ Treg approach has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results